Department of Medicine–

Paul Heidenreich, MD

Back to Profile

Publication Details

  • Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

    Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. JAMA. 2013; 309 (1): 55-62

    Randomized clinical trials have shown that implantable cardioverter-defibrillator (ICD) therapy saves lives. Whether the survival of patients who received an ICD in primary prevention clinical trials differs from that of trial-eligible patients receiving a primary prevention ICD in clinical practice is unknown.

    PubMedID: 23280225

Stanford Medicine Resources:

Footer Links: